Skip to search formSkip to main contentSkip to account menu

NSC-269148

Known as: NSC 269148, NSC269148 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Menogaril

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma
SummaryForty-five patients with non-small cell lung cancer were treated in a phase II trial with menogaril 200 mg/m2 IV every… 
1991
1991
Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.
Forty-five patients with non-small cell lung cancer were treated in a phase II trial with menogaril 200 mg/m2 IV every twenty… 
1990
1990
A phase II study of menogaril (NSC-269148) in colorectal carcinoma
SummaryIn this phase II trial, menogaril was administered to patients with metastatic colon cancer at a dose of 200 mg/m2 IV over… 
1986
1986
Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
7-con-O-Methylnogaril (menogaril, NSC-269148) is a new anthracycline antibiotic that has been evaluated in a Phase I clinical… 
1982
1982
Bioavailability and pharmacokinetics of orally administered 7-con-o-methylnogarol (7-omen: nsc269148) in the mouse. Abstr.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)